01 · Core mechanismThe dysbiosis ↔ mast cell loop
Mast cells and the microbiome regulate each other. When the microbiome becomes unbalanced, mast cells activate more intensely. When mast cells activate, they release mediators that further impoverish the microbiome. This is a vicious cycle that can sustain itself indefinitely — with no external trigger required.
The microbiome–mast cell relationship is bidirectional. Dysbiosis — often driven by diets rich in refined sugars, antibiotics, stress, or caesarean birth — triggers mast cell hyperactivation. In turn, activated mast cells release mediators that worsen dysbiosis, completing a self-sustaining loop requiring no external trigger.[1]
In the PMCHS terrain, this loop is initiated from birth on an already epigenetically lowered mast cell activation threshold. The microbiome is not the root cause — but it is one of the most powerful and accessible amplifiers to modulate.
02 · Central regulatorButyrate: the epigenetic brake on mast cells
Butyrate is a molecule produced by beneficial bacteria when they ferment dietary fibre. It is the primary natural brake on mast cells: it epigenetically locks the genes that drive their activation. Less fibre in the diet = less butyrate = mast cells running on autopilot degranulation.
Butyrate is produced from soluble fibre fermentation by commensal bacteria — mainly Faecalibacterium prausnitzii, Roseburia intestinalis, and Eubacterium hallii. It acts on mast cells through two main pathways:[2]
HDAC inhibition → chromatin condensation → repression of mast cell activation genes (FcεRI, IL-4, TNF-α)
GPR41/GPR43 receptor binding on mast cells → ↓ calcium-dependent degranulation → ↓ histamine and tryptase release
Butyrate sources compatible with PMCHS terrain
| Source | Mechanism | PMCHS tolerance |
|---|---|---|
| Blond psyllium | Fermentation → endogenous butyrate | ✅ Excellent |
| Konjac (glucomannan) | Gentle prebiotic, slow fermentation | ✅ Very well tolerated |
| Cold potato | Retrograded resistant starch | ✅ Well tolerated |
| Unripe banana (green) | Native resistant starch | ✅ Well tolerated |
| Cooked then cooled rice | Retrograded resistant starch | ✅ Neutral |
| Butter / Ghee | Direct dietary butyrate | ✅ Well tolerated |
| Microencapsulated butyrate | Extended-release supplement | ⚠️ Introduce cautiously |
| Sauerkraut, kefir, kombucha | Fermented foods | ❌ High histamine |
03 · ProtocolRecommended prebiotic fibres
Prebiotic fibres are food for beneficial bacteria. On PMCHS terrain, two criteria apply: they must be well tolerated (not too fermentable) and compatible with a low-histamine diet. Psyllium and konjac are the two pillars.
Form: 5–10g/day in a large glass of water, between meals
Why: Forms a viscous gel slowing fermentation, reduces antigenic translocation, selectively feeds bifidobacteria and Faecalibacterium
Tolerance: Excellent on MCAS terrain — start at 5g
Form: Capsules or powder, 1–3g before meals
Why: Very slow fermentation → steady butyrate production without fermentation peak → good tolerance on sensitive gut
Tolerance: Among the best on PMCHS terrain
Psyllium + cold rice or potato + ghee covers three vectors — soluble fibre, resistant starch, direct butyrate — without significant histamine burden. This is the foundation of the PMCHS microbiome protocol.
Large amounts of legumes (excessive fermentation), raw garlic and onion (histamine releasers in some), classic fermented foods (sauerkraut, kefir, kombucha).
When introducing prebiotic fibres or modifying the microbiome, a temporary worsening of symptoms (fatigue, headaches, brain fog, bloating) is possible for a few days. This phenomenon, related to a Jarisch-Herxheimer-type reaction, reflects an increased release of mediators during the rebalancing of the terrain rather than an intolerance. It is generally transient (3 to 10 days); if symptoms are marked or prolonged, reduce the dose and increase it gradually, and discuss it with your doctor.
04 · ProtocolProbiotics adapted to PMCHS terrain
Not all probiotics are equal on PMCHS terrain. Some very common strains themselves produce histamine and can worsen symptoms. Strain selection is critical. The Histamed formulation (DAO Healthcare GmbH, University of Saarland) is currently the best-adapted reference product for this terrain.
Recommended strains — per-strain rationale
| Strain | Primary action | PMCHS value |
|---|---|---|
| Bifidobacterium longum | Degrades intestinal histamine, reduces permeability | ✅ Gold standard |
| Bifidobacterium infantis | Neonatal coloniser, immune educator, gut-brain axis regulator | ✅ Essential |
| Bifidobacterium breve | Strengthens intestinal barrier, documented on atopic terrain | ✅ Recommended |
| Bifidobacterium lactis | Immunomodulation, reduces intestinal permeability | ✅ Recommended |
| Lactobacillus rhamnosus GG | Indirect mast cell stabiliser, anti-inflammatory, barrier reinforcement | ✅ PMCHS gold standard |
| Lactobacillus gasseri | Gut-brain axis, well tolerated, non-histamine-producing | ✅ Recommended |
| Lactobacillus plantarum | Actively degrades intestinal histamine | ✅ Useful (strain-dependent) |
Strains to avoid absolutely on PMCHS terrain
| Strain | Problem |
|---|---|
| Lactobacillus bulgaricus | ❌ Major histamine producer |
| Lactobacillus casei | ❌ High histamine producer |
| Streptococcus thermophilus | ❌ Histamine producer |
| Lactobacillus helveticus | ❌ Histamine producer |
| Lactobacillus reuteri | ❌ Histamine producer — aggravates PMCHS terrain |
The Histamed formulation, developed by DAO Healthcare GmbH in collaboration with the University of Saarland (Germany), contains the following six strains — all adapted to PMCHS terrain, none histamine-producing:
- Bifidobacterium longum
- Bifidobacterium infantis
- Bifidobacterium breve
- Bifidobacterium lactis
- Lactobacillus rhamnosus
- Lactobacillus gasseri
The excipient is resistant corn dextrin — itself a prebiotic, serving as a direct substrate for bifidobacteria. This is currently the most coherent probiotic formulation for PMCHS terrain available in Europe.
05 · Research hypothesisThe perinatal window and primo-colonisation
The microbiome is not built gradually — it is seeded in minutes, during passage through the birth canal. This first contact with maternal Lactobacillus and Bifidobacterium calibrates the newborn's intestinal mast cells for life. Caesarean-born children miss this foundational signal — an imbalance that can persist for years.
Neonatal primo-colonisation is the signal that trains intestinal mast cells to calibrate their activation threshold. Caesarean-born children miss passage through the birth canal and are deprived of massive exposure to maternal Lactobacillus and Bifidobacterium. Their initial microbiome, dominated by skin and hospital species, does not deliver this calibration signal, structuring a lower mast cell activation threshold from the first days of life.[3,4]
Vaginal seeding as currently practised — transfer of maternal vaginal secretions — reproduces maternal dysbiosis without correcting it. An emerging alternative: full-body immersion of caesarean newborns in a standardised preparation of selected protective strains (B. longum, B. infantis, B. breve, L. rhamnosus), independent of maternal microbiome status, within the first minutes post-birth.
This intervention would address one vector of perinatal PMCHS transmission — microbial primo-colonisation — without modifying the epigenetic and mitochondrial maternal pathways, which are not addressed by this approach.
This hypothesis is currently being formalised within the PMCHS research framework. No clinical trial has yet been conducted.
ConvergenceDysbiosis, ASD & paediatric PMCHS terrain
Autistic children consistently show lower levels of butyrate-producing bacteria than neurotypical children. This imbalance is not an isolated curiosity — it is a piece of the undiagnosed paediatric PMCHS terrain. The same strains that are missing in ASD are exactly those that brake mast cells.
Meta-analyses consistently document in ASD a depletion of Bifidobacterium, Blautia, Prevotella, and Veillonella — all short-chain fatty acid producers — alongside an overrepresentation of Clostridium and Desulfovibrio. This dysbiosis removes the double brake — butyrate and VIP (Vasoactive Intestinal Peptide, stimulated by certain Lactobacillus strains) — creating conditions for chronic intestinal mast cell hyperactivity from early infancy.
Microbiome interventions that improve ASD symptoms — L. plantarum, B. longum, prebiotics, synbiotics — likely act by restoring this butyrate/VIP double brake on intestinal mast cells operating from birth in a state of programmed hyperreactivity.
BibliographyReferences
- Xiong Y et al. Mast Cells and Microbiome in Health and Disease. Front Biosci Landmark 2025;30(3):26283.
- Folkerts J et al. The gut microbiota–mast cell axis in intestinal homeostasis and food allergy. PMC12938359, 2025.
- Dominguez-Bello MG et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. PNAS 2010;107(26):11971–11975.
- Neu J, Rushing J. Cesarean versus vaginal delivery: long-term infant outcomes and the hygiene hypothesis. Clin Perinatol 2011;38(2):321–331.
- Song Y et al. Lactobacillus casei protects intestinal barrier via VIP-mediated mast cell inhibition. PMC8657605, 2021.
- Ding HT et al. Gut microbiota and autism — systematic review. PMC6351640, 2017.
- Lu C et al. Overall Rebalancing of Gut Microbiota Is Key to Autism Intervention. Front Psychol 2022;13:862719.